association

Full identifier: http://purl.org/np/RAUaV8d5ePgHMiX1uYCXhMR6Xx5_rbO_Q3Uy5ghcwuKmQ#association

Assigned to 1 class:

Minted in Nanopublication

 RAUaV8d5eP comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RAUaV8d5eP...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "miacalcin synthetic injection is a calcitonin indicated for the following conditions 1 1 1 2 1 3 limitations of use 1 4 5 3 miacalcin injection is indicated for the treatment of symptomatic paget s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable e g patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies miacalcin injection is indicated for the early treatment of hypercalcemic emergencies along with other appropriate agents when a rapid decrease in serum calcium is required until more specific treatment of the underlying disease can be accomplished it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide oral phosphate or corticosteroids or other agents miacalcin injection is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause the evidence of efficacy for calcitonin salmon injection is based on increases in total body calcium observed in clinical trials fracture reduction efficacy has not been demonstrated miacalcin injection should be reserved for patients for whom alternative treatments are not suitable e g patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies due to the possible association between malignancy and calcitonin salmon use the need for continued therapy should be re evaluated on a periodic basis see warnings and precautions 5 3" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAUaV8d5eP... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-27T20:30:46.335+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAUaV8d5eP... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAUaV8d5eP... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAUaV8d5eP... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAUaV8d5eP...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAUaV8d5eP... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAUaV8d5eP...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 27 Jun 2021, 18:30:46 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-27T18:30:46.335Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
miacalcin synthetic injection is a calcitonin indicated for the following conditions 1 1 1 2 1 3 limitations of use 1 4 5 3 miacalcin injection is indicated for the treatment of symptomatic paget s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable e g patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies miacalcin injection is indicated for the early treatment of hypercalcemic emergencies along with other appropriate agents when a rapid decrease in serum calcium is required until more specific treatment of the underlying disease can be accomplished it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide oral phosphate or corticosteroids or other agents miacalcin injection is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause the evidence of efficacy for calcitonin salmon injection is based on increases in total body calcium observed in clinical trials fracture reduction efficacy has not been demonstrated miacalcin injection should be reserved for patients for whom alternative treatments are not suitable e g patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies due to the possible association between malignancy and calcitonin salmon use the need for continued therapy should be re evaluated on a periodic basis see warnings and precautions 5 3
Leoni Bücken
2021-06-27T18:30:46.335Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-27T18:30:46.335Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-27T18:30:46.335Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-27T18:30:46.335Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-27T18:30:46.335Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-27T18:30:46.335Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-27T18:30:46.335Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)